REFERENCES
1. Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential
treatment for COVID-19. Future Medicine; 2020.
2. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial
cluster of pneumonia associated with the 2019 novel coronavirus
indicating person-to-person transmission: a study of a family cluster.
Lancet (London, England). 2020;395(10223):514-23.
3. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and
characterisation of post-COVID-19 manifestations. International journal
of clinical practice. 2021;75(3):e13746.
4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and
diabetes mellitus at increased risk for COVID-19 infection? The Lancet
Respiratory medicine. 2020;8(4):e21.
5. Atefi N, Behrangi E, Mozafarpoor S, Seirafianpour F, Peighambari S,
Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work
as a beneficial preventive and adjuvant therapy? A comprehensive review
study. Journal of research in medical sciences : the official journal of
Isfahan University of Medical Sciences. 2020;25:109.
6. Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S,
Almasi S, et al. Cutaneous manifestations and considerations in COVID-19
pandemic: A systematic review. Dermatologic therapy. 2020;33(6):e13986.
7. Lotfi B, Farshid S, Dadashzadeh N, Valizadeh R, Rahimi MM. Is
coronavirus disease 2019 (COVID-19) associated with renal involvement? A
review of century infection. Jundishapur Journal of Microbiology.
2020;13(4):1-6.
8. Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S.
Renal and liver injury following the treatment of COVID-19 by
remdesivir. Journal of Nephropathology. 2021;10(2):1-4.
9. Tabatabaii SA, Soltani P, Khanbabaee G, Sharma D, Valizadeh R,
Farahbakhsh N, et al. SARS Coronavirus 2, Severe Acute Respiratory
Syndrome, and Middle East Respiratory Syndrome in Children: A Review on
Epidemiology, Clinical Presentation, and Diagnosis. Archives of
Pediatric Infectious Diseases. 2020;8(4).
10. Najar Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A. A
systematic review on treatment-related mucocutaneous reactions in
COVID-19 patients. Dermatologic therapy. 2021;34(1):e14662.
11. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. Journal of
medical virology. 2021;93(1):250-6.
12. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real
estimates of mortality following COVID-19 infection. The Lancet
Infectious diseases. 2020;20(7):773.
13. Daneshfar M, Dadashzadeh N, Ahmadpour M, Haghi HR, Rahmani V,
Frouzesh M, et al. Lessons of mortality following COVID-19 epidemic in
the United States especially in the geriatrics. Journal of
Nephropharmacology. 2020;10(1):e06-e.
14. Tavakolpour S, Aryanian Z, Seirafianpour F, Dodangeh M, Etesami I,
Daneshpazhooh M, et al. A systematic review on efficacy, safety, and
treatment-durability of low-dose rituximab for the treatment of
Pemphigus: special focus on COVID-19 pandemic concerns.
Immunopharmacology and Immunotoxicology. 2021:1-12.
15. Dass E. Brief review of N-acetylcysteine as antiviral agent:
potential application in COVID-19. J Biomed Pharm Res. 2020;9(3):69-73.
16. Alamdari DH, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM,
Alamdari AH, et al. Application of methylene blue-vitamin C–N-acetyl
cysteine for treatment of critically ill COVID-19 patients, report of a
phase-I clinical trial. European journal of pharmacology.
2020;885:173494.
17. Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID-19:
The potential role of copper and N-acetylcysteine (NAC) in a combination
of candidate antiviral treatments against SARS-CoV-2. in vivo. 2020;34(3
suppl):1567-88.
18. Hamad MNM. MNa Theory: Triple Therapy to COVID-19: Minocycline,
N-acetylcysteine and Aspirin. 2020.
19. Jaiswal N, Bhatnagar M, Shah H. N-acetycysteine: A potential
therapeutic agent in COVID-19 infection. Medical hypotheses.
2020;144:110133.
20. Ahmed N, Chakrabarty A, Guengerich FP, Chowdhury G. Protective role
of glutathione against peroxynitrite-mediated DNA damage during acute
inflammation. Chemical Research in Toxicology. 2020;33(10):2668-74.
21. Assimakopoulos SF, Marangos M. N-acetyl-cysteine may prevent
COVID-19-associated cytokine storm and acute respiratory distress
syndrome. Medical hypotheses. 2020;140:109778.
22. Hasan MJ. N-acetylcysteine in severe COVID-19: The possible
mechanism. International Journal of Infection. 2020;7(4).
23. Hatami N, Kalani N, Javdani F, Ahmadi SR, Habibzadeh SR, Shahi B, et
al. N-acetyl cysteine (NAC) and COVID-19 treatment: New hopes in old
medication. IJMRA. 2020;3(9).
24. Shi Z, Puyo CA. N-acetylcysteine to combat COVID-19: an evidence
review. Therapeutics and clinical risk management. 2020;16:1047.
25. Van Hecke O, Lee J. N-acetylcysteine: A rapid review of the evidence
for effectiveness in treating COVID-19. 2020.
26. Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for
SARS-CoV-2. Medical hypotheses. 2020;143:109862.
27. SJ OR. COVID-19 neurologic manifestation. Revista de la Facultad de
Ciencias Medicas (Cordoba, Argentina). 2020;77(2):130-.
28. Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of
Suspected Remdesivir‐Associated Acute Liver Failure in COVID‐19: A Case
Series. Pharmacotherapy: The Journal of Human Pharmacology and Drug
Therapy. 2020;40(11):1166-71.
29. Sarkar S, Rapista N, Jean L-G. Corona virus disease-19-induced acute
liver failure leading to severe metabolic acidosis. Chest.
2020;158(4):A1002.
30. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K,
Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm
and AstraZeneca vaccines to stop COVID-19; a review and discussion.
2021.
31. Hołyńska-Iwan I, Wróblewski M, Olszewska-Słonina D, Tyrakowski T.
The application of N-acetylcysteine in optimization of specific
pharmacological therapies. Polski merkuriusz lekarski: organ Polskiego
Towarzystwa Lekarskiego. 2017;43(255):140-4.
32. Cadegiani FA. Repurposing existing drugs for COVID-19: an
endocrinology perspective. BMC endocrine disorders. 2020;20(1):149.
33. De Flora S, Balansky R, La Maestra S. Rationale for the use of
N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.
FASEB journal : official publication of the Federation of American
Societies for Experimental Biology. 2020;34(10):13185-93.
34. Fregatti P, Gipponi M, Giacchino M, Sparavigna M, Diaz R, Fioravanti
E, et al. Breast Cancer Surgery in the COVID-19 Pandemic: Validation of
a Preventive Program for Patients and Health Care Workers. In Vivo.
2021;35(1):635-9.
35. de Alencar JCG, Moreira CL, Müller AD, Chaves CE, Fukuhara MA, da
Silva EA, et al. Double-blind, Randomized, Placebo-controlled Trial With
N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome
Caused by Coronavirus Disease 2019 (COVID-19). Clinical infectious
diseases : an official publication of the Infectious Diseases Society of
America. 2021;72(11):e736-e41.
36. Daid SS, Toribio AD, Lakshmanan S, Sadda A, Epstein A. Spontaneous
Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19. Cureus.
2020;12(9):e10447.
37. Elgamasy S, Kamel MG, Ghozy S, Khalil A, Morra ME, Islam SMS. First
case of focal epilepsy associated with SARS-coronavirus-2. Journal of
medical virology. 2020;92(10):2238-42.
38. Goodnough R, Canseco K. Truncated IV acetylcysteine treatment
duration has potential to safely preserve resources during the COVID-19
pandemic. Clinical toxicology (Philadelphia, Pa). 2021;59(1):69.
39. Goodnough R, Canseco K. Response to Comment on Truncated IV
acetylcysteine treatment duration has potential to safely preserve
resources during the COVID-19 pandemic. Clinical toxicology
(Philadelphia, Pa). 2021;59(1):78-9.
40. Horowitz RI, Freeman PR. Three novel prevention, diagnostic, and
treatment options for COVID-19 urgently necessitating controlled
randomized trials. Med Hypotheses. 2020;143:109851.
41. Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al.
Therapeutic blockade of inflammation in severe COVID-19 infection with
intravenous N-acetylcysteine. Clinical immunology (Orlando, Fla).
2020;219:108544.
42. Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al.
Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Nature reviews Immunology. 2020;20(9):515-6.
43. Luo P, Liu Y, Liu D, Li J. Perspectives for the Use of
N-acetylcysteine as a Candidate Drug to Treat COVID-19. Mini reviews in
medicinal chemistry. 2021;21(3):268-72.
44. Meletis CD, Wilkes K. Immune Competence and Minimizing
Susceptibility to COVID-19 and Other Immune System Threats. Alternative
therapies in health and medicine. 2020;26(S2):94-9.
45. Nasi A, McArdle S, Gaudernack G, Westman G, Melief C, Rockberg J, et
al. Reactive oxygen species as an initiator of toxic innate immune
responses in retort to SARS-CoV-2 in an ageing population, consider
N-acetylcysteine as early therapeutic intervention. Toxicology reports.
2020;7:768-71.
46. Wong A. Comment on Truncated IV acetylcysteine treatment duration
has potential to safely preserve resources during the COVID-19 pandemic.
Clinical toxicology (Philadelphia, Pa). 2021;59(1):77-8.
47. Zhou N, Yang X, Huang A, Chen Z. The potential mechanism of
N-acetylcysteine in treating COVID-19. Current pharmaceutical
biotechnology. 2020.
48. Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of
N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review
of current evidence. European review for medical and pharmacological
sciences. 2021;25(6):2802-7.
49. Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL,
van der Voort PHJ, et al. N-Acetylcysteine and Hydrogen Sulfide in
Coronavirus Disease 2019. Antioxidants & redox signaling. 2021.
50. Mashayekhi F, Seirafianpour F, Pour Mohammad A, Goodarzi A. Severe
and life-threatening COVID-19-related mucocutaneous eruptions: A
systematic review. International journal of clinical practice.
2021:e14720.
51. Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione therapy
in relieving dyspnea associated with COVID-19 pneumonia: A report of 2
cases. Respiratory medicine case reports. 2020;30:101063.
52. Mohamadi M, Goodarzi A, Aryannejad A, Fattahi N, Alizadeh-Khoei M,
Miri S, et al. Geriatric challenges in the new coronavirus disease-19
(COVID-19) pandemic: A systematic review. Medical journal of the Islamic
Republic of Iran. 2020;34:123.
53. Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A,
Hanifiha M, Goodarzi A. Treatment of COVID-19 with pentoxifylline: Could
it be a potential adjuvant therapy? Dermatologic therapy.
2020;33(4):e13733.
54. Nobari NN, Goodarzi A. Patients with specific skin disorders who are
affected by COVID-19: What do experiences say about management
strategies? A systematic review. Dermatologic therapy.
2020;33(6):e13867.
55. Sadeghzadeh-Bazargan A, Behrangi E, Goodarzi A. Systemic retinoids
in the COVID-19 era–are they helpful, safe, or harmful? a comprehensive
systematized review. Iranian Journal of Dermatology. 2020;23(Suppl. 1
(COVID-19)):9-12.
56. Bazargan M, Behrangi E, Goodarzi A. Cytokine storm and probable role
of immunoregulatory drugs in COVID-19: a comprehensive review. Iranian
Journal of Dermatology.23:1.
57. Goodarzi A. A comprehensive review on COVID-19 infection and
comorbidities of various organs. Acta Medica Iranica. 2021:4-14.
58. Kalantari S, Sadeghzadeh-Bazargan A, Ebrahimi S, Yassin Z, Faiz SHR,
Kabir A, et al. The effect of influenza vaccine on severity of COVID-19
infection: An original study from Iran. Medical Journal of The Islamic
Republic of Iran (MJIRI). 2021;35(1):865-9.
59. Kooranifar S, Sadeghipour A, Riahi T, Goodarzi A, Tabrizi S, Davoody
N. Histopathologic survey on lung necropsy specimens of 15 patients who
died from COVID-19: A large study from Iran with a high rate of
anthracosis. Medical Journal of The Islamic Republic of Iran (MJIRI).
2021;35(1):481-90.
60. Najar Nobari N, Seirafianpour F, Dodangeh M, Sadeghzadeh‐Bazargan A,
Behrangi E, Mozafarpoor S, et al. A systematic review of the
histopathologic survey on skin biopsies in patients with Corona Virus
Disease 2019 (COVID‐19) who developed virus or drug‐related
mucocutaneous manifestations. Experimental dermatology. 2021.
61. Nobari NN, Montazer F, Seirafianpour F, Goodarzi A. Histopathologic
changes and cellular events of organs systems in COVID-19. Journal of
Cellular and Molecular Anesthesia. 2021;6(1):81-8.
62. Sadeghzadeh‐Bazargan A, Rezai M, Nobari NN, Mozafarpoor S, Goodarzi
A. Skin manifestations as potential symptoms of diffuse vascular injury
in critical COVID‐19 patients. Journal of cutaneous pathology. 2021.
63. Riahi T, Sadeghzadeh-Bazargan A, Shokri S, Ahmadvand D, Hassanlouei
B, Baghestani A, et al. The effect of opium on severity of COVID-19
infection: An original study from Iran. Medical Journal of The Islamic
Republic of Iran (MJIRI). 2021;35(1):870-4.